Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
BMC Cancer|October 30, 2019
SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocolRobert Olson, Roel Schlijper, Nick Chng, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 2022
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 TrialSarah Baker, Benjamin Mou, Will Jiang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 23, 2025
Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapyEmily O'Reilly, Eshawn Johal, Haley Clark, et al.
Brachytherapy|September 12, 2016
Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiationBradley J Stish, Deanna H Pafundi, Tina J Hieken, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 TrialSarah Baker, Will Jiang, Benjamin Mou, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2025
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 TrialSarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, et al.
BMC Cancer|October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5Robert Olson, Mitchell Liu, Alanah Bergman, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2025
Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapyJonas Willmann, Sarah Baker, Hanbo Chen, et al.
BMC Cancer|May 7, 2020
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trialRobert Olson, Lindsay Mathews, Mitchell Liu, et al.
JAMA Oncology|September 29, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical TrialRobert Olson, Will Jiang, Mitchell Liu, et al.
Pageof 4